Skip to content

Vir Biotechnology, Inc. VIR Short- term Investments

Short- term Investments at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Gilead Sciences logo
Gilead SciencesGILD
Nuvation Bio logo
Nuvation BioNUVB
Enliven Therapeutics logo
Enliven TherapeuticsELVN
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Biohaven logo
BiohavenBHVN

Other financials

Income statement

See full
Revenue-$29.0K-101%
Gross profit$1.2M-60.2%
Operating income-$132.3M+5.2%
Net income-$125.7M-3.9%
EPS (diluted)-$0.85+3.4%

Balance sheet

See full
Cash & equivalents$283.0M-23.1%
Total debt$95.6M-0.5%
Total equity$812.8M-22.1%
Total assets$1.0B-21.6%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$390.0K-76.1%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.71B+61.1%
Enterprise value$1.53B+102%
P/S26.2×-24.8×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-720.8%-313pp
Net margin-676%-291pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-47.7%+3.6pp
Debt / equity0.1×0.0×
Current ratio7.1×+0.3×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vir Biotechnology, Inc.'s short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vir Biotechnology, Inc.'s short- term investments?
Vir Biotechnology, Inc. (VIR) reported short- term investments of $196.28M in Q1 2026.
How has Vir Biotechnology, Inc.'s short- term investments changed year-over-year?
Vir Biotechnology, Inc.'s short- term investments decreased by 62.1% year-over-year, from $517.37M to $196.28M.
What is the long-term trend for Vir Biotechnology, Inc.'s short- term investments?
Over 5 years (2020 to 2025), Vir Biotechnology, Inc.'s short- term investments has grown at a -5.3% compound annual growth rate (CAGR), from $300.29M to $228.75M.